Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)(Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics))

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

TILS Shanghai Gencells Therapeutics、Tumor infiltrating lymphocytes Shanghai Gencells Therapeutics

靶点-

作用机制

免疫细胞毒性、T淋巴细胞替代物

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

8

项与 Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics) 相关的临床试验

NCT05087745 / Recruiting早期临床1期

A Clinical Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

开始日期2021-12-10

申办/合作机构

上海君赛生物科技有限公司

[+1]

NCT05142475 / Recruiting早期临床1期

A Clinical Study on TIL for the Treatment of Advanced Breast Cancer

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

开始日期2021-11-19

申办/合作机构

上海君赛生物科技有限公司

[+1]

NCT05098184 / Recruiting早期临床1期

A Clinical Study on TIL for the Treatment of Advanced Melanoma

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

开始日期2021-09-26

申办/合作机构

上海君赛生物科技有限公司

[+1]

100 项与 Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	中国	上海君赛生物科技有限公司	2021-12-10
胃肠道间质瘤	临床1期	中国	上海君赛生物科技有限公司	2021-06-27
胶质瘤	临床1期	中国	上海君赛生物科技有限公司	2021-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SITC2017	N/A	黑色素瘤	-	Tumor Infiltrating Lymphocytes (TIL) (Polystyrene 24-well culture plates)	鏇鏇網艱鏇觸網窪網顧(獵齋窪鹹醖淵憲觸構蓋) = 窪夢獵選憲網繭構遞鬱範餘遞獵鑰積壓製簾鹽 (範構鹽築淵餘醖衊繭窪, 14) 更多	积极	2017-11-07
				Tumor Infiltrating Lymphocytes (TIL) (Gas-permeable (G-REX) 24-well culture plates)	鏇鏇網艱鏇觸網窪網顧(獵齋窪鹹醖淵憲觸構蓋) = 鏇糧艱衊鏇築範鏇範鑰範餘遞獵鑰積壓製簾鹽 (範構鹽築淵餘醖衊繭窪, 8) 更多